nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—G alpha (q) signalling events—F2R—melanoma	0.00288	0.00655	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR1—melanoma	0.00287	0.00652	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—F2R—melanoma	0.00285	0.00647	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—MC1R—melanoma	0.00283	0.00642	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDNRB—melanoma	0.00279	0.00634	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDNRB—melanoma	0.00276	0.00626	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR7—melanoma	0.00271	0.00616	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL4—melanoma	0.00264	0.006	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GNA11—melanoma	0.00264	0.00599	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—E2F1—melanoma	0.00263	0.00597	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—melanoma	0.00258	0.00586	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PRKCA—melanoma	0.00257	0.00585	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—F2RL1—melanoma	0.00253	0.00575	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—melanoma	0.0025	0.00567	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GNAQ—melanoma	0.00245	0.00557	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCR4—melanoma	0.00245	0.00556	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—RAC1—melanoma	0.00239	0.00542	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GRM3—melanoma	0.00238	0.00541	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—melanoma	0.00236	0.00536	CbGpPWpGaD
Fosaprepitant—Blood pressure increased—Docetaxel—melanoma	0.00229	0.00408	CcSEcCtD
Fosaprepitant—Muscular weakness—Carmustine—melanoma	0.00228	0.00407	CcSEcCtD
Fosaprepitant—Hypokalaemia—Temozolomide—melanoma	0.00227	0.00406	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CDK2—melanoma	0.00227	0.00515	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—KISS1—melanoma	0.00226	0.00513	CbGpPWpGaD
Fosaprepitant—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00225	0.00401	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00225	0.00401	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—melanoma	0.00225	0.0051	CbGpPWpGaD
Fosaprepitant—Hypotension—Vemurafenib—melanoma	0.00224	0.00401	CcSEcCtD
Fosaprepitant—Stomatitis—Bleomycin—melanoma	0.00222	0.00397	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—TAS2R60—melanoma	0.00222	0.00504	CbGpPWpGaD
Fosaprepitant—Muscular weakness—Temozolomide—melanoma	0.0022	0.00393	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Temozolomide—melanoma	0.0022	0.00393	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—melanoma	0.00219	0.00498	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TLR4—melanoma	0.00219	0.00497	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCR1—melanoma	0.00218	0.00497	CbGpPWpGaD
Fosaprepitant—Candida infection—Docetaxel—melanoma	0.00218	0.0039	CcSEcCtD
Fosaprepitant—Haematuria—Bleomycin—melanoma	0.00217	0.00388	CcSEcCtD
Fosaprepitant—Abdominal distension—Temozolomide—melanoma	0.00217	0.00388	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—melanoma	0.00217	0.00494	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—MC1R—melanoma	0.00215	0.00489	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CDK4—melanoma	0.00214	0.00487	CbGpPWpGaD
Fosaprepitant—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00211	0.00377	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—ICAM1—melanoma	0.0021	0.00477	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Vemurafenib—melanoma	0.00209	0.00373	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—NOS2—melanoma	0.00208	0.00473	CbGpPWpGaD
Fosaprepitant—Stomatitis—Dactinomycin—melanoma	0.00207	0.0037	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Vemurafenib—melanoma	0.00207	0.0037	CcSEcCtD
Fosaprepitant—Fatigue—Vemurafenib—melanoma	0.00207	0.0037	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCR7—melanoma	0.00206	0.00469	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GRM1—melanoma	0.00206	0.00469	CbGpPWpGaD
Fosaprepitant—Constipation—Vemurafenib—melanoma	0.00205	0.00367	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Bleomycin—melanoma	0.00204	0.00364	CcSEcCtD
Fosaprepitant—Dysuria—Temozolomide—melanoma	0.00202	0.0036	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—TAS2R60—melanoma	0.00202	0.00458	CbGpPWpGaD
Fosaprepitant—Pollakiuria—Temozolomide—melanoma	0.00199	0.00356	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Temozolomide—melanoma	0.00197	0.00352	CcSEcCtD
Fosaprepitant—Weight decreased—Temozolomide—melanoma	0.00195	0.00349	CcSEcCtD
Fosaprepitant—Stomatitis—Carmustine—melanoma	0.00194	0.00347	CcSEcCtD
Fosaprepitant—Urinary tract infection—Carmustine—melanoma	0.00193	0.00346	CcSEcCtD
Fosaprepitant—Infestation—Temozolomide—melanoma	0.00192	0.00344	CcSEcCtD
Fosaprepitant—Infestation NOS—Temozolomide—melanoma	0.00192	0.00344	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Docetaxel—melanoma	0.00192	0.00342	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—F2R—melanoma	0.00191	0.00434	CbGpPWpGaD
Fosaprepitant—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.00191	0.00341	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00191	0.00341	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDN1—melanoma	0.0019	0.00432	CbGpPWpGaD
Fosaprepitant—Flushing—Bleomycin—melanoma	0.0019	0.00339	CcSEcCtD
Fosaprepitant—Body temperature increased—Vemurafenib—melanoma	0.0019	0.00339	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDN1—melanoma	0.00188	0.00426	CbGpPWpGaD
Fosaprepitant—Stomatitis—Temozolomide—melanoma	0.00188	0.00335	CcSEcCtD
Fosaprepitant—Urinary tract infection—Temozolomide—melanoma	0.00187	0.00334	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—RB1—melanoma	0.00186	0.00423	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDNRB—melanoma	0.00185	0.0042	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HIF1A—melanoma	0.00183	0.00416	CbGpPWpGaD
Fosaprepitant—Erythema multiforme—Dactinomycin—melanoma	0.00181	0.00322	CcSEcCtD
Fosaprepitant—Erythema—Bleomycin—melanoma	0.00178	0.00318	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Carmustine—melanoma	0.00178	0.00318	CcSEcCtD
Fosaprepitant—Hot flush—Docetaxel—melanoma	0.00177	0.00317	CcSEcCtD
Fosaprepitant—Flushing—Dactinomycin—melanoma	0.00177	0.00316	CcSEcCtD
Fosaprepitant—Hypersensitivity—Vemurafenib—melanoma	0.00177	0.00316	CcSEcCtD
Fosaprepitant—Menopausal symptoms—Docetaxel—melanoma	0.00176	0.00314	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Carmustine—melanoma	0.00176	0.00314	CcSEcCtD
Fosaprepitant—Asthenia—Vemurafenib—melanoma	0.00172	0.00308	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Temozolomide—melanoma	0.00172	0.00307	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CXCR2—melanoma	0.00171	0.00389	CbGpPWpGaD
Fosaprepitant—Urinary tract disorder—Temozolomide—melanoma	0.00171	0.00305	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—melanoma	0.0017	0.00386	CbGpPWpGaD
Fosaprepitant—Pruritus—Vemurafenib—melanoma	0.0017	0.00303	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Temozolomide—melanoma	0.0017	0.00303	CcSEcCtD
Fosaprepitant—Lethargy—Docetaxel—melanoma	0.00169	0.00303	CcSEcCtD
Fosaprepitant—Urethral disorder—Temozolomide—melanoma	0.00169	0.00302	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL1—melanoma	0.00168	0.00382	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PLCB4—melanoma	0.00168	0.00382	CbGpPWpGaD
Fosaprepitant—Eye disorder—Carmustine—melanoma	0.00167	0.00298	CcSEcCtD
Fosaprepitant—Hyponatraemia—Docetaxel—melanoma	0.00167	0.00298	CcSEcCtD
Fosaprepitant—Erythema—Dactinomycin—melanoma	0.00166	0.00297	CcSEcCtD
Fosaprepitant—Flushing—Carmustine—melanoma	0.00166	0.00296	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—WNT5A—melanoma	0.00166	0.00376	CbGpPWpGaD
Fosaprepitant—Ill-defined disorder—Bleomycin—melanoma	0.00165	0.00295	CcSEcCtD
Fosaprepitant—Anaemia—Bleomycin—melanoma	0.00165	0.00294	CcSEcCtD
Fosaprepitant—Diarrhoea—Vemurafenib—melanoma	0.00164	0.00293	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR4—melanoma	0.00164	0.00373	CbGpPWpGaD
Fosaprepitant—Erythema multiforme—Temozolomide—melanoma	0.00163	0.00292	CcSEcCtD
Fosaprepitant—Eye disorder—Temozolomide—melanoma	0.00161	0.00288	CcSEcCtD
Fosaprepitant—Tinnitus—Temozolomide—melanoma	0.00161	0.00288	CcSEcCtD
Fosaprepitant—Malaise—Bleomycin—melanoma	0.00161	0.00287	CcSEcCtD
Fosaprepitant—Flushing—Temozolomide—melanoma	0.0016	0.00286	CcSEcCtD
Fosaprepitant—Cardiac disorder—Temozolomide—melanoma	0.0016	0.00286	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IFNG—melanoma	0.0016	0.00363	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCA—melanoma	0.00159	0.00362	CbGpPWpGaD
Fosaprepitant—Dizziness—Vemurafenib—melanoma	0.00159	0.00283	CcSEcCtD
Fosaprepitant—Angiopathy—Temozolomide—melanoma	0.00157	0.0028	CcSEcCtD
Fosaprepitant—Mental disorder—Carmustine—melanoma	0.00157	0.0028	CcSEcCtD
Fosaprepitant—Immune system disorder—Temozolomide—melanoma	0.00156	0.00279	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K2—melanoma	0.00156	0.00354	CbGpPWpGaD
Fosaprepitant—Mediastinal disorder—Temozolomide—melanoma	0.00156	0.00278	CcSEcCtD
Fosaprepitant—Erythema—Carmustine—melanoma	0.00156	0.00278	CcSEcCtD
Fosaprepitant—Malnutrition—Carmustine—melanoma	0.00156	0.00278	CcSEcCtD
Fosaprepitant—Cough—Bleomycin—melanoma	0.00156	0.00278	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Dactinomycin—melanoma	0.00154	0.00275	CcSEcCtD
Fosaprepitant—Anaemia—Dactinomycin—melanoma	0.00154	0.00274	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—melanoma	0.00153	0.00348	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL1—melanoma	0.00153	0.00347	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PLCB4—melanoma	0.00153	0.00347	CbGpPWpGaD
Fosaprepitant—Vomiting—Vemurafenib—melanoma	0.00153	0.00273	CcSEcCtD
Fosaprepitant—Chest pain—Bleomycin—melanoma	0.00152	0.00271	CcSEcCtD
Fosaprepitant—Abdominal pain upper—Docetaxel—melanoma	0.00152	0.00271	CcSEcCtD
Fosaprepitant—Rash—Vemurafenib—melanoma	0.00151	0.0027	CcSEcCtD
Fosaprepitant—Mental disorder—Temozolomide—melanoma	0.00151	0.0027	CcSEcCtD
Fosaprepitant—Dermatitis—Vemurafenib—melanoma	0.00151	0.0027	CcSEcCtD
Fosaprepitant—Headache—Vemurafenib—melanoma	0.0015	0.00269	CcSEcCtD
Fosaprepitant—Erythema—Temozolomide—melanoma	0.0015	0.00268	CcSEcCtD
Fosaprepitant—Malnutrition—Temozolomide—melanoma	0.0015	0.00268	CcSEcCtD
Fosaprepitant—Discomfort—Bleomycin—melanoma	0.0015	0.00268	CcSEcCtD
Fosaprepitant—Malaise—Dactinomycin—melanoma	0.0015	0.00268	CcSEcCtD
Fosaprepitant—Toxic epidermal necrolysis—Docetaxel—melanoma	0.00149	0.00267	CcSEcCtD
Fosaprepitant—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00149	0.00267	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—melanoma	0.00148	0.00337	CbGpPWpGaD
Fosaprepitant—Dysgeusia—Temozolomide—melanoma	0.00147	0.00263	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Docetaxel—melanoma	0.00146	0.00261	CcSEcCtD
Fosaprepitant—Oedema—Bleomycin—melanoma	0.00145	0.0026	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Bleomycin—melanoma	0.00145	0.0026	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—F2R—melanoma	0.00145	0.0033	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CDKN1B—melanoma	0.00145	0.00329	CbGpPWpGaD
Fosaprepitant—Infection—Bleomycin—melanoma	0.00144	0.00258	CcSEcCtD
Fosaprepitant—Anaemia—Carmustine—melanoma	0.00144	0.00257	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—F2RL1—melanoma	0.00143	0.00325	CbGpPWpGaD
Fosaprepitant—Nausea—Vemurafenib—melanoma	0.00143	0.00255	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CASP3—melanoma	0.00142	0.00323	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL2—melanoma	0.00142	0.00322	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDNRB—melanoma	0.00141	0.0032	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYO7A—melanoma	0.0014	0.00318	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—DRAP1—melanoma	0.0014	0.00318	CbGpPWpGaD
Fosaprepitant—Discomfort—Dactinomycin—melanoma	0.0014	0.0025	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Temozolomide—melanoma	0.00139	0.00249	CcSEcCtD
Fosaprepitant—Anaemia—Temozolomide—melanoma	0.00139	0.00248	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—CCND1—melanoma	0.00138	0.00314	CbGpPWpGaD
Fosaprepitant—Angioedema—Temozolomide—melanoma	0.00137	0.00245	CcSEcCtD
Fosaprepitant—Hypotension—Bleomycin—melanoma	0.00136	0.00243	CcSEcCtD
Fosaprepitant—Oedema—Dactinomycin—melanoma	0.00136	0.00242	CcSEcCtD
Fosaprepitant—Malaise—Temozolomide—melanoma	0.00136	0.00242	CcSEcCtD
Fosaprepitant—Infection—Dactinomycin—melanoma	0.00135	0.00241	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GRM3—melanoma	0.00134	0.00306	CbGpPWpGaD
Fosaprepitant—Hypertension—Carmustine—melanoma	0.00134	0.0024	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—melanoma	0.00134	0.00305	CbGpPWpGaD
Fosaprepitant—Palpitations—Temozolomide—melanoma	0.00133	0.00237	CcSEcCtD
Fosaprepitant—Chest pain—Carmustine—melanoma	0.00132	0.00237	CcSEcCtD
Fosaprepitant—Anxiety—Carmustine—melanoma	0.00132	0.00236	CcSEcCtD
Fosaprepitant—Cough—Temozolomide—melanoma	0.00131	0.00234	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—F2RL1—melanoma	0.0013	0.00295	CbGpPWpGaD
Fosaprepitant—Weight decreased—Docetaxel—melanoma	0.0013	0.00232	CcSEcCtD
Fosaprepitant—Hypertension—Temozolomide—melanoma	0.0013	0.00232	CcSEcCtD
Fosaprepitant—Dyspnoea—Bleomycin—melanoma	0.0013	0.00232	CcSEcCtD
Fosaprepitant—Infestation—Docetaxel—melanoma	0.00128	0.00228	CcSEcCtD
Fosaprepitant—Infestation NOS—Docetaxel—melanoma	0.00128	0.00228	CcSEcCtD
Fosaprepitant—Anxiety—Temozolomide—melanoma	0.00128	0.00228	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—KISS1—melanoma	0.00127	0.0029	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00127	0.00227	CcSEcCtD
Fosaprepitant—Oedema—Carmustine—melanoma	0.00127	0.00227	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00127	0.00226	CcSEcCtD
Fosaprepitant—Discomfort—Temozolomide—melanoma	0.00126	0.00226	CcSEcCtD
Fosaprepitant—Decreased appetite—Bleomycin—melanoma	0.00126	0.00226	CcSEcCtD
Fosaprepitant—Infection—Carmustine—melanoma	0.00126	0.00225	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDN1—melanoma	0.00126	0.00286	CbGpPWpGaD
Fosaprepitant—Dry mouth—Temozolomide—melanoma	0.00125	0.00224	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CXCR4—melanoma	0.00125	0.00284	CbGpPWpGaD
Fosaprepitant—Stomatitis—Docetaxel—melanoma	0.00125	0.00223	CcSEcCtD
Fosaprepitant—Pain—Bleomycin—melanoma	0.00124	0.00222	CcSEcCtD
Fosaprepitant—Conjunctivitis—Docetaxel—melanoma	0.00124	0.00222	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCR1—melanoma	0.00123	0.00281	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Temozolomide—melanoma	0.00123	0.00219	CcSEcCtD
Fosaprepitant—Oedema—Temozolomide—melanoma	0.00123	0.00219	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GRM3—melanoma	0.00122	0.00278	CbGpPWpGaD
Fosaprepitant—Infection—Temozolomide—melanoma	0.00122	0.00218	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—MC1R—melanoma	0.00122	0.00276	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Temozolomide—melanoma	0.0012	0.00215	CcSEcCtD
Fosaprepitant—Feeling abnormal—Bleomycin—melanoma	0.0012	0.00214	CcSEcCtD
Fosaprepitant—Skin disorder—Temozolomide—melanoma	0.00119	0.00213	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TAS2R60—melanoma	0.00119	0.00271	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—melanoma	0.00119	0.0027	CbGpPWpGaD
Fosaprepitant—Hypotension—Carmustine—melanoma	0.00119	0.00212	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Temozolomide—melanoma	0.00119	0.00212	CcSEcCtD
Fosaprepitant—Decreased appetite—Dactinomycin—melanoma	0.00118	0.00211	CcSEcCtD
Fosaprepitant—Fatigue—Dactinomycin—melanoma	0.00117	0.00209	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CCR7—melanoma	0.00117	0.00265	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GRM1—melanoma	0.00117	0.00265	CbGpPWpGaD
Fosaprepitant—Pain—Dactinomycin—melanoma	0.00116	0.00207	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—KISS1—melanoma	0.00116	0.00263	CbGpPWpGaD
Fosaprepitant—Urticaria—Bleomycin—melanoma	0.00116	0.00206	CcSEcCtD
Fosaprepitant—Body temperature increased—Bleomycin—melanoma	0.00115	0.00205	CcSEcCtD
Fosaprepitant—Insomnia—Carmustine—melanoma	0.00115	0.00205	CcSEcCtD
Fosaprepitant—Hypoaesthesia—Docetaxel—melanoma	0.00114	0.00204	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MAPK3—melanoma	0.00114	0.00259	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—melanoma	0.00114	0.00258	CbGpPWpGaD
Fosaprepitant—Urinary tract disorder—Docetaxel—melanoma	0.00113	0.00203	CcSEcCtD
Fosaprepitant—Dyspnoea—Carmustine—melanoma	0.00113	0.00202	CcSEcCtD
Fosaprepitant—Somnolence—Carmustine—melanoma	0.00113	0.00202	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Docetaxel—melanoma	0.00113	0.00202	CcSEcCtD
Fosaprepitant—Urethral disorder—Docetaxel—melanoma	0.00113	0.00201	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CXCR1—melanoma	0.00112	0.00255	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Dactinomycin—melanoma	0.00112	0.002	CcSEcCtD
Fosaprepitant—Insomnia—Temozolomide—melanoma	0.00111	0.00198	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MYC—melanoma	0.00111	0.00252	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Dactinomycin—melanoma	0.00111	0.00198	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—MC1R—melanoma	0.0011	0.00251	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—melanoma	0.0011	0.00251	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Carmustine—melanoma	0.0011	0.00197	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Carmustine—melanoma	0.0011	0.00196	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.0011	0.00249	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Temozolomide—melanoma	0.00109	0.00195	CcSEcCtD
Fosaprepitant—Somnolence—Temozolomide—melanoma	0.00109	0.00195	CcSEcCtD
Fosaprepitant—Erythema multiforme—Docetaxel—melanoma	0.00109	0.00194	CcSEcCtD
Fosaprepitant—Constipation—Carmustine—melanoma	0.00109	0.00194	CcSEcCtD
Fosaprepitant—Pain—Carmustine—melanoma	0.00109	0.00194	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MAPK1—melanoma	0.00109	0.00247	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—melanoma	0.00109	0.00247	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Temozolomide—melanoma	0.00108	0.00193	CcSEcCtD
Fosaprepitant—Eye disorder—Docetaxel—melanoma	0.00107	0.00192	CcSEcCtD
Fosaprepitant—Body temperature increased—Dactinomycin—melanoma	0.00107	0.00191	CcSEcCtD
Fosaprepitant—Abdominal pain—Dactinomycin—melanoma	0.00107	0.00191	CcSEcCtD
Fosaprepitant—Hypersensitivity—Bleomycin—melanoma	0.00107	0.00191	CcSEcCtD
Fosaprepitant—Decreased appetite—Temozolomide—melanoma	0.00107	0.0019	CcSEcCtD
Fosaprepitant—Flushing—Docetaxel—melanoma	0.00107	0.0019	CcSEcCtD
Fosaprepitant—Cardiac disorder—Docetaxel—melanoma	0.00107	0.0019	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NFKB1—melanoma	0.00106	0.00241	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RHOB—melanoma	0.00106	0.00241	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Temozolomide—melanoma	0.00106	0.00189	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GRM1—melanoma	0.00106	0.00241	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCR7—melanoma	0.00106	0.00241	CbGpPWpGaD
Fosaprepitant—Fatigue—Temozolomide—melanoma	0.00106	0.00189	CcSEcCtD
Fosaprepitant—Pain—Temozolomide—melanoma	0.00105	0.00187	CcSEcCtD
Fosaprepitant—Constipation—Temozolomide—melanoma	0.00105	0.00187	CcSEcCtD
Fosaprepitant—Feeling abnormal—Carmustine—melanoma	0.00105	0.00187	CcSEcCtD
Fosaprepitant—Asthenia—Bleomycin—melanoma	0.00104	0.00186	CcSEcCtD
Fosaprepitant—Angiopathy—Docetaxel—melanoma	0.00104	0.00186	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Carmustine—melanoma	0.00104	0.00185	CcSEcCtD
Fosaprepitant—Immune system disorder—Docetaxel—melanoma	0.00104	0.00185	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Docetaxel—melanoma	0.00104	0.00185	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—melanoma	0.00103	0.00235	CbGpPWpGaD
Fosaprepitant—Pruritus—Bleomycin—melanoma	0.00103	0.00184	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—melanoma	0.00101	0.0023	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Temozolomide—melanoma	0.00101	0.00181	CcSEcCtD
Fosaprepitant—Mental disorder—Docetaxel—melanoma	0.00101	0.0018	CcSEcCtD
Fosaprepitant—Body temperature increased—Carmustine—melanoma	0.001	0.00179	CcSEcCtD
Fosaprepitant—Abdominal pain—Carmustine—melanoma	0.001	0.00179	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Temozolomide—melanoma	0.001	0.00179	CcSEcCtD
Fosaprepitant—Erythema—Docetaxel—melanoma	0.001	0.00179	CcSEcCtD
Fosaprepitant—Malnutrition—Docetaxel—melanoma	0.001	0.00179	CcSEcCtD
Fosaprepitant—Hypersensitivity—Dactinomycin—melanoma	0.000999	0.00178	CcSEcCtD
Fosaprepitant—Dysgeusia—Docetaxel—melanoma	0.000979	0.00175	CcSEcCtD
Fosaprepitant—Urticaria—Temozolomide—melanoma	0.000975	0.00174	CcSEcCtD
Fosaprepitant—Asthenia—Dactinomycin—melanoma	0.000973	0.00174	CcSEcCtD
Fosaprepitant—Body temperature increased—Temozolomide—melanoma	0.00097	0.00173	CcSEcCtD
Fosaprepitant—Abdominal pain—Temozolomide—melanoma	0.00097	0.00173	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCR2—melanoma	0.000966	0.0022	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—melanoma	0.000964	0.00219	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RHOB—melanoma	0.000963	0.00219	CbGpPWpGaD
Fosaprepitant—Muscle spasms—Docetaxel—melanoma	0.000961	0.00172	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—EDN1—melanoma	0.000958	0.00218	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RAC2—melanoma	0.000951	0.00216	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Carmustine—melanoma	0.000935	0.00167	CcSEcCtD
Fosaprepitant—Diarrhoea—Dactinomycin—melanoma	0.000928	0.00166	CcSEcCtD
Fosaprepitant—Vomiting—Bleomycin—melanoma	0.000925	0.00165	CcSEcCtD
Fosaprepitant—Anaemia—Docetaxel—melanoma	0.000924	0.00165	CcSEcCtD
Fosaprepitant—Rash—Bleomycin—melanoma	0.000917	0.00164	CcSEcCtD
Fosaprepitant—Dermatitis—Bleomycin—melanoma	0.000916	0.00164	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—melanoma	0.000911	0.00207	CbGpPWpGaD
Fosaprepitant—Asthenia—Carmustine—melanoma	0.000911	0.00163	CcSEcCtD
Fosaprepitant—Hypersensitivity—Temozolomide—melanoma	0.000904	0.00161	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CXCL1—melanoma	0.000902	0.00205	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PLCB4—melanoma	0.000902	0.00205	CbGpPWpGaD
Fosaprepitant—Syncope—Docetaxel—melanoma	0.000897	0.0016	CcSEcCtD
Fosaprepitant—Palpitations—Docetaxel—melanoma	0.000883	0.00158	CcSEcCtD
Fosaprepitant—Asthenia—Temozolomide—melanoma	0.00088	0.00157	CcSEcCtD
Fosaprepitant—Loss of consciousness—Docetaxel—melanoma	0.000879	0.00157	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CXCR2—melanoma	0.000877	0.00199	CbGpPWpGaD
Fosaprepitant—Cough—Docetaxel—melanoma	0.000872	0.00156	CcSEcCtD
Fosaprepitant—Diarrhoea—Carmustine—melanoma	0.000869	0.00155	CcSEcCtD
Fosaprepitant—Pruritus—Temozolomide—melanoma	0.000868	0.00155	CcSEcCtD
Fosaprepitant—Nausea—Bleomycin—melanoma	0.000864	0.00154	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—RAC2—melanoma	0.000863	0.00196	CbGpPWpGaD
Fosaprepitant—Hypertension—Docetaxel—melanoma	0.000863	0.00154	CcSEcCtD
Fosaprepitant—Vomiting—Dactinomycin—melanoma	0.000862	0.00154	CcSEcCtD
Fosaprepitant—Rash—Dactinomycin—melanoma	0.000855	0.00153	CcSEcCtD
Fosaprepitant—Chest pain—Docetaxel—melanoma	0.000851	0.00152	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—WNT5A—melanoma	0.00085	0.00193	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CUL3—melanoma	0.000849	0.00193	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TRRAP—melanoma	0.000849	0.00193	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000845	0.00151	CcSEcCtD
Fosaprepitant—Dizziness—Carmustine—melanoma	0.00084	0.0015	CcSEcCtD
Fosaprepitant—Diarrhoea—Temozolomide—melanoma	0.000839	0.0015	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—melanoma	0.000834	0.0019	CbGpPWpGaD
Fosaprepitant—Dry mouth—Docetaxel—melanoma	0.000832	0.00149	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—melanoma	0.000827	0.00188	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKR1B10—melanoma	0.000825	0.00188	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—F2R—melanoma	0.000822	0.00187	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Docetaxel—melanoma	0.000816	0.00146	CcSEcCtD
Fosaprepitant—Oedema—Docetaxel—melanoma	0.000816	0.00146	CcSEcCtD
Fosaprepitant—Dizziness—Temozolomide—melanoma	0.000811	0.00145	CcSEcCtD
Fosaprepitant—Infection—Docetaxel—melanoma	0.000811	0.00145	CcSEcCtD
Fosaprepitant—Vomiting—Carmustine—melanoma	0.000807	0.00144	CcSEcCtD
Fosaprepitant—Nausea—Dactinomycin—melanoma	0.000806	0.00144	CcSEcCtD
Fosaprepitant—Shock—Docetaxel—melanoma	0.000803	0.00143	CcSEcCtD
Fosaprepitant—Rash—Carmustine—melanoma	0.0008	0.00143	CcSEcCtD
Fosaprepitant—Nervous system disorder—Docetaxel—melanoma	0.0008	0.00143	CcSEcCtD
Fosaprepitant—Dermatitis—Carmustine—melanoma	0.0008	0.00143	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—EDNRB—melanoma	0.000796	0.00181	CbGpPWpGaD
Fosaprepitant—Headache—Carmustine—melanoma	0.000795	0.00142	CcSEcCtD
Fosaprepitant—Skin disorder—Docetaxel—melanoma	0.000793	0.00142	CcSEcCtD
Fosaprepitant—Vomiting—Temozolomide—melanoma	0.00078	0.00139	CcSEcCtD
Fosaprepitant—Rash—Temozolomide—melanoma	0.000774	0.00138	CcSEcCtD
Fosaprepitant—Dermatitis—Temozolomide—melanoma	0.000773	0.00138	CcSEcCtD
Fosaprepitant—Headache—Temozolomide—melanoma	0.000769	0.00137	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—F2RL1—melanoma	0.000767	0.00174	CbGpPWpGaD
Fosaprepitant—Hypotension—Docetaxel—melanoma	0.000762	0.00136	CcSEcCtD
Fosaprepitant—Nausea—Carmustine—melanoma	0.000754	0.00135	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GAB2—melanoma	0.000751	0.00171	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GNA11—melanoma	0.000751	0.00171	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—F2R—melanoma	0.000746	0.0017	CbGpPWpGaD
Fosaprepitant—Insomnia—Docetaxel—melanoma	0.000738	0.00132	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—melanoma	0.000737	0.00167	CbGpPWpGaD
Fosaprepitant—Nausea—Temozolomide—melanoma	0.000729	0.0013	CcSEcCtD
Fosaprepitant—Dyspnoea—Docetaxel—melanoma	0.000727	0.0013	CcSEcCtD
Fosaprepitant—Somnolence—Docetaxel—melanoma	0.000725	0.0013	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EDNRB—melanoma	0.000723	0.00164	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRM3—melanoma	0.000721	0.00164	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Docetaxel—melanoma	0.000718	0.00128	CcSEcCtD
Fosaprepitant—Decreased appetite—Docetaxel—melanoma	0.000709	0.00127	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCR4—melanoma	0.000706	0.00161	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—melanoma	0.000706	0.0016	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Docetaxel—melanoma	0.000704	0.00126	CcSEcCtD
Fosaprepitant—Fatigue—Docetaxel—melanoma	0.000703	0.00126	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GNAQ—melanoma	0.000699	0.00159	CbGpPWpGaD
Fosaprepitant—Constipation—Docetaxel—melanoma	0.000698	0.00125	CcSEcCtD
Fosaprepitant—Pain—Docetaxel—melanoma	0.000698	0.00125	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—KISS1—melanoma	0.000684	0.00155	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNA11—melanoma	0.000682	0.00155	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GAB2—melanoma	0.000682	0.00155	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.00068	0.00155	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Docetaxel—melanoma	0.000672	0.0012	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—melanoma	0.000672	0.00153	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—melanoma	0.000671	0.00153	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Docetaxel—melanoma	0.000667	0.00119	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—melanoma	0.000667	0.00152	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SKI—melanoma	0.000662	0.00151	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCR1—melanoma	0.000662	0.00151	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MC1R—melanoma	0.000652	0.00148	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3CA—melanoma	0.000652	0.00148	CbGpPWpGaD
Fosaprepitant—Abdominal pain—Docetaxel—melanoma	0.000645	0.00115	CcSEcCtD
Fosaprepitant—Body temperature increased—Docetaxel—melanoma	0.000645	0.00115	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT3—melanoma	0.000645	0.00147	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCR4—melanoma	0.000642	0.00146	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GNAQ—melanoma	0.000634	0.00144	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—melanoma	0.000634	0.00144	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCR7—melanoma	0.000626	0.00142	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRM1—melanoma	0.000626	0.00142	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SUFU—melanoma	0.00061	0.00139	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Docetaxel—melanoma	0.000601	0.00107	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—AKT3—melanoma	0.000585	0.00133	CbGpPWpGaD
Fosaprepitant—Asthenia—Docetaxel—melanoma	0.000585	0.00105	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—melanoma	0.000583	0.00132	CbGpPWpGaD
Fosaprepitant—Pruritus—Docetaxel—melanoma	0.000577	0.00103	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RHOB—melanoma	0.000569	0.00129	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BCL2L11—melanoma	0.000569	0.00129	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Docetaxel—melanoma	0.000558	0.000997	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—HDAC6—melanoma	0.000547	0.00124	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—EDN1—melanoma	0.000542	0.00123	CbGpPWpGaD
Fosaprepitant—Dizziness—Docetaxel—melanoma	0.00054	0.000963	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—melanoma	0.000539	0.00123	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CSF2—melanoma	0.000529	0.0012	CbGpPWpGaD
Fosaprepitant—Vomiting—Docetaxel—melanoma	0.000519	0.000926	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CXCR2—melanoma	0.000518	0.00118	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—melanoma	0.000518	0.00118	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—melanoma	0.000516	0.00117	CbGpPWpGaD
Fosaprepitant—Rash—Docetaxel—melanoma	0.000514	0.000919	CcSEcCtD
Fosaprepitant—Dermatitis—Docetaxel—melanoma	0.000514	0.000918	CcSEcCtD
Fosaprepitant—Headache—Docetaxel—melanoma	0.000511	0.000913	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RAC2—melanoma	0.00051	0.00116	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCA—melanoma	0.000508	0.00115	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—WNT5A—melanoma	0.000502	0.00114	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFC—melanoma	0.000502	0.00114	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EDN1—melanoma	0.000492	0.00112	CbGpPWpGaD
Fosaprepitant—Nausea—Docetaxel—melanoma	0.000485	0.000865	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CSF2—melanoma	0.000481	0.00109	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—RAC1—melanoma	0.000471	0.00107	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCA—melanoma	0.000461	0.00105	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAP2K2—melanoma	0.000451	0.00102	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—F2R—melanoma	0.000441	0.001	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—RAC1—melanoma	0.000427	0.000971	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDNRB—melanoma	0.000427	0.00097	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTK2B—melanoma	0.000414	0.000942	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GAB2—melanoma	0.000403	0.000916	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNA11—melanoma	0.000403	0.000916	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FLT1—melanoma	0.000401	0.000912	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CG—melanoma	0.000398	0.000904	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCR4—melanoma	0.000379	0.000861	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HDAC2—melanoma	0.000379	0.000861	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FOXO4—melanoma	0.000379	0.000861	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNAQ—melanoma	0.000375	0.000852	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CG—melanoma	0.000361	0.00082	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SYK—melanoma	0.000352	0.000801	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CD—melanoma	0.00035	0.000794	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NGFR—melanoma	0.000346	0.000786	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT3—melanoma	0.000346	0.000786	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ITGAV—melanoma	0.000346	0.000786	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SOCS1—melanoma	0.00032	0.000728	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAP2K1—melanoma	0.000319	0.000726	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—S100B—melanoma	0.000319	0.000726	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CD—melanoma	0.000317	0.000721	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB4—melanoma	0.000305	0.000694	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CB—melanoma	0.000305	0.000692	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN2B—melanoma	0.000303	0.000688	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CD86—melanoma	0.000293	0.000666	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—melanoma	0.000293	0.000665	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDN1—melanoma	0.000291	0.00066	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGF1—melanoma	0.000284	0.000645	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CSF2—melanoma	0.000284	0.000645	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IL2—melanoma	0.00028	0.000636	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—E2F1—melanoma	0.000278	0.000632	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CB—melanoma	0.000277	0.000629	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDGFRA—melanoma	0.000275	0.000625	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ITGB3—melanoma	0.000272	0.000619	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCA—melanoma	0.000272	0.000619	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SPP1—melanoma	0.000267	0.000607	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAP2K2—melanoma	0.000266	0.000605	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—melanoma	0.000266	0.000604	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL2—melanoma	0.000254	0.000577	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TERT—melanoma	0.000253	0.000575	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RAC1—melanoma	0.000252	0.000574	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HIF1A—melanoma	0.000242	0.00055	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KDR—melanoma	0.000232	0.000526	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FN1—melanoma	0.000223	0.000506	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH1—melanoma	0.000218	0.000496	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CD80—melanoma	0.000214	0.000486	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APC—melanoma	0.000213	0.000485	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KIT—melanoma	0.000213	0.000485	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CG—melanoma	0.000213	0.000485	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—NRAS—melanoma	0.000213	0.000485	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGF—melanoma	0.000211	0.000479	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAPK3—melanoma	0.000204	0.000464	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—BRAF—melanoma	0.0002	0.000456	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—melanoma	0.000195	0.000444	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MAPK1—melanoma	0.000194	0.000442	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—melanoma	0.000194	0.000442	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAP2K1—melanoma	0.000189	0.000429	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CD—melanoma	0.000187	0.000426	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3CA—melanoma	0.000186	0.000422	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—KRAS—melanoma	0.000184	0.000417	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—FGF2—melanoma	0.00018	0.000408	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3CA—melanoma	0.000169	0.000383	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MDM2—melanoma	0.000168	0.000382	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB2—melanoma	0.000166	0.000376	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CB—melanoma	0.000163	0.000371	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—melanoma	0.000157	0.000357	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HRAS—melanoma	0.000156	0.000355	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1B—melanoma	0.000153	0.000349	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—melanoma	0.000152	0.000345	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASP3—melanoma	0.00015	0.000342	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL2—melanoma	0.00015	0.000341	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—melanoma	0.000149	0.000339	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCND1—melanoma	0.000146	0.000333	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CTNNB1—melanoma	0.000145	0.000329	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—melanoma	0.000142	0.000323	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN1A—melanoma	0.000142	0.000322	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTEN—melanoma	0.000141	0.000321	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NFKB1—melanoma	0.000141	0.000319	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—melanoma	0.000138	0.000313	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—melanoma	0.000128	0.00029	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—STAT3—melanoma	0.000126	0.000287	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NRAS—melanoma	0.000126	0.000286	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK3—melanoma	0.000121	0.000274	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MYC—melanoma	0.000117	0.000267	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MAPK1—melanoma	0.000115	0.000261	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—melanoma	0.000115	0.000261	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KRAS—melanoma	0.000108	0.000246	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3CA—melanoma	9.96e-05	0.000226	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—melanoma	9.64e-05	0.000219	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HRAS—melanoma	9.22e-05	0.000209	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—melanoma	8.82e-05	0.0002	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—melanoma	8.14e-05	0.000185	CbGpPWpGaD
